

Reference number
2181-A

# SPECIALTY GUIDELINE MANAGEMENT

## SAMSCA (tolvaptan) tolvaptan

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Treatment of clinically significant hypovolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

##### *Important Limitations*

Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with Samsca/tolvaptan. It has not been established that raising serum sodium with Samsca/tolvaptan provides a symptomatic benefit to patients.

All other indications are considered experimental/investigational and are not medically necessary.

#### II. CRITERIA FOR INITIAL APPROVAL

##### **Hypovolemic/Euvolemic Hyponatremia**

Authorization of 30 days may be granted for members prescribed the requested drug when all of the following criteria are met:

- A. Therapy was initiated (or re-initiated) in the hospital for hypovolemic or euvolemic hyponatremia.
- B. Serum sodium was less than 125 mEq/L or serum sodium was less than 135 mEq/L with symptoms (e.g., nausea, vomiting, headache, lethargy, confusion) at the time of therapy initiation.
- C. The member will not receive the requested drug continually for greater than 30 days.

#### III. REFERENCES

1. Samsca [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; April 2021.
2. Tolvaptan [package insert]. Parsippany, NJ: Novadoz Pharmaceuticals LLC; March 2023.
3. Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: Compilation of the guidelines. *J Am Soc Nephrol.* 2017; 28(5):1340-1349.